Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL- positive acute lymphoblastic leukemia
| Autor: | Yasutaka Aoyama, Yasushi Miyazaki, Kazuhiko Kakihana, Kiyotoshi Imai, Yasunori Ueda, Tomoki Naoe, Kazunori Ohnishi, Shuichi Mizuta, Nobuaki Dobashi, Shigeki Ohtake, Hideki Akiyama, Keitaro Matsuo, Isamu Sugiura, Shin Fujisawa, Yoshihiro Hatta, Yasushi Onishi, Tomoya Maeda |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.medical_treatment Fusion Proteins bcr-abl Phases of clinical research Philadelphia chromosome Gastroenterology Young Adult 03 medical and health sciences 0302 clinical medicine Recurrence hemic and lymphatic diseases Internal medicine medicine Humans Transplantation Homologous Survival rate Survival analysis Chemotherapy business.industry Remission Induction Hematopoietic Stem Cell Transplantation Imatinib Hematology Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Survival Analysis Surgery Consolidation Chemotherapy Survival Rate Transplantation Clinical trial Treatment Outcome 030220 oncology & carcinogenesis Imatinib Mesylate Female business 030215 immunology medicine.drug |
| Zdroj: | American Journal of Hematology. 92:367-374 |
| ISSN: | 0361-8609 |
| Popis: | This study investigated the efficacy of imatinib based therapy with intensified consolidation therapy in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) to prevent early relapse. We conducted a phase II trial of imatinib-combined chemotherapy for newly diagnosed BCR-ABL-positive ALL in adults. Sixty-eight patients were included in the trial between October 2008 and December 2010. The median age was 49 years, with 28 patients55 years of age. Sixty-five patients achieved CR (95.6%). The estimated 2-year event-free survival (EFS) and overall survival (OS) were 62.3% and 67.4%, respectively. Allogeneic stem cell transplantation (allo-SCT) at initial CR was performed in 43 patients. Thirty-five of 39 patients55 years and 8 of 26 patients55 years underwent allo-SCT at first CR. The 3-year OS in patients55 years receiving allo-SCT at first CR, patients55 years receiving allo-SCT at first CR, patients55 years not receiving allo-SCT at first CR, and patients55 years not receiving allo-SCT at first CR were 80.4%, 41.1%, 32.5%, and 52.0%, respectively (P = 0.058). The three-year EFS in each group was 76.7%, 53.6%, not reached, and 26.4%, respectively (P = 0.150). A high CR rate was observed with imatinib-based chemotherapy allowing allo-SCT in a high proportion of patients, particularly those55 years. Moreover, intensified consolidation therapy reduced early relapse rates following induction therapy and resulted in improved OS and EFS rates following allo-SCT. This trial was registered with the UMIN (000001226). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text